Zacks Investment Research upgraded shares of ANTARES PHARMA (ATRS) from UNDERPERFORM to NEUTRAL on September 07, 2012, with a target price of $4.10.
Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ANTARES PHARMA (ATRS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment